<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377362</url>
  </required_header>
  <id_info>
    <org_study_id>GLWL-SMP</org_study_id>
    <nct_id>NCT02377362</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01</brief_title>
  <official_title>A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, and Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GLWL Research Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GLWL Research Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 3-part study will explore the safety and tolerability of GLWL-01 in overweight/obese
      healthy participants after single doses (in Part A), and in participants with type 2 diabetes
      mellitus after multiple doses during a 28-day period (Parts B and C).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient efficacy for this indication
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">November 9, 2016</completion_date>
  <primary_completion_date type="Actual">November 9, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Treatment Emergent Adverse Events (Part A)</measure>
    <time_frame>Baseline to 11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with One or More Treatment Emergent Adverse Events (Parts B &amp; C)</measure>
    <time_frame>Baseline to 32 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Non-Zero Concentration (AUC0-t) (Part A)</measure>
    <time_frame>Pre-dose and up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Non-Zero Concentration (AUC0-t) (Parts B &amp; C)</measure>
    <time_frame>24 Hours Post-Dose on Day 1 up to 42 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to 24-hour Post-Dose (AUC0-24) (Part A)</measure>
    <time_frame>Pre-dose and up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to 24-hour Post-Dose (AUC0-24) (Parts B &amp; C)</measure>
    <time_frame>24 Hours Post-Dose on Day 1 up to 42 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC-inf) (Part A)</measure>
    <time_frame>Pre-dose and up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC-inf) (Parts B &amp; C)</measure>
    <time_frame>24 Hours Post-Dose on Day 1 up to 42 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) (Part A)</measure>
    <time_frame>Pre-dose and up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) (Parts B &amp; C)</measure>
    <time_frame>24 Hours Post-Dose on Day 1 up to 42 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Observed Cmax (Tmax) (Part A)</measure>
    <time_frame>Pre-dose and up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Observed Cmax (Tmax) (Parts B &amp; C)</measure>
    <time_frame>24 Hours Post-Dose on Day 1 up to 42 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (T1/2) (Part A)</measure>
    <time_frame>Pre-dose and up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (T1/2) (Parts B &amp; C)</measure>
    <time_frame>24 Hours Post-Dose on Day 1 up to 42 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of Drug (CL/F) (Part A)</measure>
    <time_frame>Pre-dose and up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of Drug (CL/F) (Parts B &amp; C)</measure>
    <time_frame>24 Hours Post-Dose on Day 1 up to 42 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Volume of Distribution (VZ/F) (Part A)</measure>
    <time_frame>Pre-dose and up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Volume of Distribution (VZ/F) (Parts B &amp; C)</measure>
    <time_frame>24 Hours Post-Dose on Day 1 up to 42 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Drug Excreted in Urine (Aet1-t12) (Part A)</measure>
    <time_frame>Pre-Dose and 12 hours Post-Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Drug Excreted in Urine (Aet1-t12) (Part B)</measure>
    <time_frame>Pre-Dose and 12 hours Post-Dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Drug Excreted in Urine (Aet0-24) (Part A)</measure>
    <time_frame>Pre-Dose and 24-hours Post-Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Drug Excreted in Urine (Aet0-24) (Part B)</measure>
    <time_frame>Pre-Dose and 24-hours Post-Dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Drug Excreted in the Urine (Fe) (Part A)</measure>
    <time_frame>Pre-Dose and 24-hours Post-Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Drug Excreted in the Urine (Fe) (Part B)</measure>
    <time_frame>Pre-Dose and 24-hours Post-Dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Plasma Glucose Concentration After Multiple Doses (Parts B &amp; C)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Glucose (Parts B &amp; C)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Peptide Concentration (Parts B &amp; C)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Concentration (Parts B &amp; C)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose Concentration (Parts B &amp; C)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (Parts B &amp; C)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference (Parts B &amp; C)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip Circumference (Parts B &amp; C)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>GLWL-01, Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose in at least 2 of 3 periods, starting at 10 milligrams (mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Escalating dose of placebo to match GLWL-01, in 1 period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLWL-01, Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending daily doses of GLWL-01 at up to six dose levels, based on Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple daily doses of placebo to match GLWL-01</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLWL-01, Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple daily doses of GLWL-01 at level based upon Part B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Part C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple daily doses of placebo to match GLWL-01</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLWL-01, Part A</intervention_name>
    <description>Capsules administered orally, in 2 out of 3 periods</description>
    <arm_group_label>GLWL-01, Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, Part A</intervention_name>
    <description>Capsules administered orally in 1 out of 3 periods</description>
    <arm_group_label>Placebo, Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLWL-01, Part B</intervention_name>
    <description>Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28</description>
    <arm_group_label>GLWL-01, Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, Part B</intervention_name>
    <description>Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
    <arm_group_label>Placebo, Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLWL-01, Part C</intervention_name>
    <description>Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
    <arm_group_label>GLWL-01, Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, Part C</intervention_name>
    <description>Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
    <arm_group_label>Placebo, Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        PARTS A-C:

          -  Non-vasectomized males (or those vasectomized less than 4 months prior to study start)
             must agree to use a condom with spermicide or abstain from sexual intercourse during
             the study until 90 days beyond the last dose of study drug

          -  Males agree to not donate sperm from dosing until 90 days after dosing

          -  Laboratory test results within normal range or acceptable deviation, and Aspartate
             Aminotransferase (AST) / Alanine Aminotransferase (ALT) / Gamma Glutamyl Transferase
             (GGT) / Alkaline Phosphatase (ALP) to be less than or equal to (≤)1.5 x upper limit of
             normal (ULN), and total bilirubin has to be within normal limit

          -  Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 60 milliliter
             (mL)/minute/1.73m2

          -  No evidence of weight excursion beyond 5% of baseline weight within 3 months of
             screening

        PART A Only:

          -  Overtly healthy males or females, as determined by medical history and physical
             examination

          -  Males must be 18 to 65 years old; females must be 40 to 65 years old

          -  Female participants must be:

               1. Women with prior history of hysterectomy who are at least 45 years of age and
                  with follicle-stimulating hormone (FSH) greater than (&gt;) 40 milli-international
                  units per milliliter (mIU/mL), or

               2. Menopausal women with either: spontaneous amenorrhea for at least 12 months (not
                  induced by a medical condition or medications); or spontaneous amenorrhea for 6
                  to 12 months and a FSH &gt; 40 mIU/mL

          -  Body mass index (BMI) of 28 to 35 kilograms divided by height in meters squared
             (kg/m2)

          -  Normotensive (supine systolic blood pressure (BP) less than (&lt;) 140 millimeter of
             mercury (mmHg) and diastolic BP &lt;90 mmHg

          -  No evidence of weight excursion beyond 5% of baseline weight within 3 months of
             screening

        PARTS B and C:

          -  Must have Type 2 Diabetes Mellitus

          -  Be 18 to 70 years old

          -  Have BMI of 28 to 42 kg/m2

          -  Female participants must be of non-childbearing potential, and must have undergone one
             of the following sterilization procedures at least 6 months prior to first dose:
             hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy,
             hysterectomy, or bilateral oophorectomy; or be postmenopausal with amenorrhea for at
             least 1 year prior to the first dose and with FSH serum levels consistent with
             postmenopausal status

          -  Normotensive (supine systolic BP) &lt; 150 mmHg and diastolic BP &lt;95 mmHg or
             well-controlled hypertension while on a stable hypertensive

        Exclusion Criteria:

        PARTS A-C:

          -  Currently enrolled in a clinical trial or any other medical research judged to be not
             compatible with the study, or have participated in the last 30 days prior to dosing in
             a clinical trial involving an investigational product or non-approved use of a drug
             with short half-life, or within 5 half-lives of an investigational product with a
             half-life longer than 6 days

          -  Abnormality in the 12-lead electrocardiogram (ECG) including corrected QT (QTc)
             interval with Bazett's correction &gt;450 milliseconds (msec) for men and &gt;470 msec for
             women, or an abnormality that, in the opinion of the Investigator, increases the risks
             associated with participating in the study

          -  Significant cardiovascular disease or other disorders

          -  Evidence of human immunodeficiency virus (HIV) infection, hepatitis B, hepatitis C, or
             other chronic liver or biliary disease

          -  Average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per
             week (females), or is unwilling to stop use of Cytochrome P450 (CYP3A)
             inhibitors/inducers (St. John's Wort) or alcohol consumption for the study, or regular
             use of known drugs of abuse or positive finding on urinary drug screen, use of
             cigarettes or nicotine products within last 3 months, or blood donation or loss within
             56 days prior to the study

          -  Neuropsychiatric disease or pharmacological therapy for such conditions within 1 year
             of dosing, or antidepressants or antipsychotics within 3 months of dosing, or surgery
             within last 60 days

          -  Eating disorder or weight loss medications within 4 months of dosing, or bariatric
             surgery

          -  Unsuitable for inclusion in the study in the opinion of the investigator or sponsor

        PART A Only:

          -  History of hypertension (or on treatment with any antihypertensives)

          -  Endocrine illness such as diabetes, growth hormone insufficiency / acromegaly, adrenal
             gland or thyroid illness

        PARTS B and C:

          -  Currently taking simvastatin &gt; 10 mg per day, or atorvastatin &gt; 20 mg per day, or
             lovastatin &gt;20 mg per day, or history of statin-induced myopathy / rhabdomyolysis.
             Participants taking any dose of simvastatin will be excluded from some cohorts

          -  Allergic to the components of the Mixed Meal Tolerance Test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email: GLWL@Choruspharma.com</last_name>
    <role>Study Director</role>
    <affiliation>GLWL Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 30, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

